Skip to nav Skip to content

Clinical Trial Search

303 Clinical Trials Found

Clinical Trial 21892

A Phase 2, Single-Arm, Open-Label Study using Itacitinib as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 21921

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma
Disease Site: Breast, Liver, Other Digestive Organ, Other Female Genital, Ovary
PI: Soliman, Hatem

Clinical Trial 22286

Disease Site: Leukemia, other
PI: Shah, Bijal

Clinical Trial 22380

A Phase II Multicenter, Open Label, Non-Randomized Study of Neoadjuvant and Adjuvant Treatment with IPH5201 and Durvalumab in Patients with Resectable, Early-Stage (II To IIIA) Non-Small Cell Lung CancEr (MATISSE)
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 20178

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Disease Site: Lung, Non small cell lung cancer
PI: Saltos, Andreas

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Disease Site: Bones and Joints, Rhabdomyosarcoma
PI: Metts, Jonathan

Clinical Trial 20110

GBM Agile: Global Adaptive Trial Master Protocol
Disease Site: Brain and Nervous System
PI: Grogan, Patrick

Clinical Trial 21143

Disease Site: Mycosis Fungoides
PI: Sokol, Lubomir

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 20871

A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Disease Site: Unknown Sites
PI: Nishihori, Taiga

Clinical Trial 20415

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Safety And Efficacy Of Polatuzumab Vedotin In Combination With RituximabI Plus Gemcitabine Plus Oxaliplatin (R-Gemox) Versus R-Gemox Alone In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Disease Site: Myeloid and Monocytic Leukemia
PI: Sandoval-Sus, Jose